Oss, The Netherlands, July 3, 2019 —hannounced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V., BOM Brabant Ventures, BrightGene, and Curie Capital. The proceeds will be used to progress the pre-clinical and clinical development of Citryll’s tACPA antibodies, inhibitors of neutrophil extracellular traps (NETs) and their formation (NETosis).… Read More


Renato Chirivi, Ph.D. Head Internal Therapeutic development and Helmuth van Es, Ph.D. CEO of Citryll will be attending the annual meeting of the American College for Rheumatology in San Francisco. The conference will be held from 8-11 November at the Moscone Center in San Francisco. We will be presenting the tACPA programme and its NETosis… Read More